HIV-1 adaptation to HLA-restricted immune responses

Information

  • Research Project
  • 7232379
  • ApplicationId
    7232379
  • Core Project Number
    R01AI060460
  • Full Project Number
    5R01AI060460-04
  • Serial Number
    60460
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/15/2004 - 21 years ago
  • Project End Date
    2/28/2009 - 16 years ago
  • Program Officer Name
    EMBRY, ALAN C.
  • Budget Start Date
    3/1/2007 - 18 years ago
  • Budget End Date
    2/29/2008 - 17 years ago
  • Fiscal Year
    2007
  • Support Year
    4
  • Suffix
  • Award Notice Date
    4/9/2007 - 18 years ago
Organizations

HIV-1 adaptation to HLA-restricted immune responses

DESCRIPTION (provided by applicant): HIV-1 has a remarkable capacity to adapt to individual human hosts by escaping cytotoxic T lymphocyte (CTL) responses mediated by human leukocyte antigen (HLA) recognition. Though HLA types are highly polymorphic, and there is site-specific functional constraint to change in the virus, HIV-1 appears to escape HLA-restricted CTL (and possibly CD4 T helper cell) responses by genetic mutation. Here, the study of HLA-driven adaptation at a population level will be used to understand determinants of HIV-1 disease severity in the HIV-1 infected individual and to guide design of a vaccine that would most effectively overcome the adaptability of HIV-1 in human populations. The specific aims are to: 1) Characterize HIV-1 adaptation to HLA at a (host) population level to identify immune escape/adaptations across full length HIV-1 sequences in a large drug-naive cohort that has HLA and viral diversity representative of populations in the US; 2) Correlate HLA-driven adaptation to viral load; 3) Determine immunological and virological determinants of HLA-driven adaptation and viral load. The sites of HLA-associated selection will mark out in vivo epitope targets of immune responses and the viral load effects of escape at these sites serve as a quantitative measure of the balance between host immune pressure and genetic barrier to mutation unique to every specific escape/adaptation. The information will be used to (i) correlate in-vivo HLA class I selection effects with assayed ex-vivo CTL responses (ii) define novel CTL and CD4 T helper epitopes (ii) measure magnitude, phenotype and T cell receptor (TCR) characteristics of T cells that favour or mitigate specific adaptations and (iii) measure the replicative fitness cost that constrains immune selection at these sites; 4) Design a 'population-optimised' HIV-1 vaccine. The results will be used to determine how well the immune responses induced by a given vaccine would recognise diverse, variably HLA-adapted HIV-1 strains at those epitopes most critical for the prevalent HLA types of the study cohort.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    237045
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:237045\
  • Funding Mechanism
  • Study Section
    AIP
  • Study Section Name
    AIDS Immunology and Pathogenesis Study Section
  • Organization Name
    MURDOCH UNIVERSITY
  • Organization Department
  • Organization DUNS
    740094610
  • Organization City
    PERTH
  • Organization State
  • Organization Country
    AUSTRALIA
  • Organization Zip Code
    6150
  • Organization District
    AUSTRALIA